SCHEMBL79673

SCHEMBL79673

CC(C)(C)OC(=O)NC1(CO)COC(C)(C)OC1

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.35
HCRTR2 O43614 1/20 0.34
GAA P10253 3/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
MAPK1 P28482 1/20 0.33
ASGR1 P07306 1/20 0.33
APLNR P35414 1/20 0.33
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
CA7 P43166 1/20 0.31
CTSL P07711 2/20 0.31
CTSD P07339 1/20 0.31
CTSB P07858 1/20 0.31
CTSS P25774 1/20 0.31
P2RX7 Q99572 1/20 0.31
CTSK P43235 1/20 0.31
EPHX1 P07099 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29169997 0.88 HCRTR2 (0.34) TDP1HCRTR2GAAMEN1KMT2A
SCHEMBL24071385 0.85 P2RX7 (0.37) TDP1GAAMEN1KMT2AMAPK1
SCHEMBL6823332 0.85 GAA (0.39) TDP1HCRTR2GAAMEN1KMT2A
SCHEMBL1222522 0.85 HCRTR2 (0.33) TDP1HCRTR2GAAMEN1KMT2A
SCHEMBL437782 0.83 TDP1 (0.33) TDP1HCRTR2
SCHEMBL24071256 0.81 CTSL (0.35) TDP1HCRTR2GAAMEN1KMT2A
SCHEMBL29674156 0.81 TDP1 (0.35) TDP1HCRTR2GAAMEN1KMT2A
SCHEMBL565122 0.80 CA12 (0.31) HCRTR2CA1CA2CA7
SCHEMBL436763 0.80 APLNR (0.31) HCRTR2APLNR
SCHEMBL14733194 0.80 SPHK1 (0.38) TDP1MEN1KMT2AAPLNRCA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12570617-B2 Use of triazole compound as ghrelin receptor agonist KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) 2026-03-10 US disclosed
US-12398109-B2 2-amino-2-(1,2,3-triazole-4-yl)propane-1,3-diol derivative of novel compound for directly inhibiting ASM activity, and use thereof KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) 2025-08-26 US disclosed
CN-120081796-A Use of triazole compounds as gastric somatostatin receptor agonists 庆北大学校产学协力团 2025-06-03 CN disclosed
CN-116669575-B Use of triazole compounds as gastric somatostatin receptor agonists 庆北大学校产学协力团 2025-04-04 CN disclosed
EP-3789380-B1 2-AMINO-2-(1,2,3-TRIAZOLE-4-YL)PROPANE-1,3-DIOL DERIVATIVE OF NOVEL COMPOUND FOR DIRECTLY INHIBITING ASM ACTIVITY, AND USE THEREOF KYUNGPOOK NAT UNIV IND ACADEMIC COOP FOUND (KR) 2024-12-04 EP disclosed
WO-2024175677-A1 PROBES FOR DISTINCTION OF STERILE AND BACTERIAL INFECTION Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) 2024-08-29 WO disclosed
CN-112351974-B Novel compound 2-amino-2- (1, 2, 3-triazole-4-yl) -1, 3-propanediol derivative capable of directly inhibiting ASM activity and application thereof 庆北大学校产学协力团 2024-01-26 CN disclosed
US-20230339869-A1 USE OF TRIAZOLE COMPOUND AS GHRELIN RECEPTOR AGONIST KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) 2023-10-26 US disclosed
US-20230339869-A1 USE OF TRIAZOLE COMPOUND AS GHRELIN RECEPTOR AGONIST KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) 2023-10-26 US disclosed
US-20230339869-A1 USE OF TRIAZOLE COMPOUND AS GHRELIN RECEPTOR AGONIST KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) 2023-10-26 US disclosed
US-7560477-B2 Compounds active in sphingosine 1-phosphate signaling UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2009-07-14 US disclosed
US-20090137530-A1 Amine Compound and Use Thereof for Medical Purposes MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-05-28 US disclosed
US-20090137530-A1 Amine Compound and Use Thereof for Medical Purposes MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-05-28 US disclosed
US-20090137530-A1 Amine Compound and Use Thereof for Medical Purposes MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-05-28 US disclosed
EP-1961734-A1 AMINE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES Mitsubishi Tanabe Pharma Corporation (JP) 2008-08-27 EP disclosed
WO-2008030118-A1 ACYCLIC AMINE INHIBITORS OF 5'-METHYLTHIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE INDUSTRIAL RESEARCH LIMITED (NZ) 2008-03-13 WO disclosed
WO-2008030119-A1 ACYCLIC AMINE INHIBITORS OF NUCLEOSIDE PHOSPHORYLASES AND HYDROLASES INDUSTRIAL RESEARCH LIMITED (NZ) 2008-03-13 WO disclosed
US-20070219163-A1 Compounds Active in Sphingosine 1-Phosphate Signaling UNIVERSITY OF VIRGINIA PATENT FOUNDATION 2007-09-20 US disclosed
US-7241790-B2 Compounds active in spinigosine 1-phosphate signaling UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2007-07-10 US disclosed
US-20070088002-A1 Orally available sphingosine 1-phosphate receptor agonists and antagonists NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2007-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137530-A1 Amine Compound and Use Thereof for Medical Purposes HRH3, HRH2, HRH4 TDP1 3754/4885HCRTR2 96/4885GAA 3585/4885
US-20070088002-A1 Orally available sphingosine 1-phosphate receptor agonists and antagonists S1PR3, S1PR1, S1PR5 TDP1 2387/4885HCRTR2 127/4885GAA 4375/4885
US-12570617-B2 Use of triazole compound as ghrelin receptor agonist GIPR, GLP1R, GCGR TDP1 4547/4885HCRTR2 436/4885GAA 3251/4885
US-20230339869-A1 USE OF TRIAZOLE COMPOUND AS GHRELIN RECEPTOR AGONIST GIPR, GPR119, GLP1R TDP1 4580/4885HCRTR2 124/4885GAA 1471/4885
US-12398109-B2 2-amino-2-(1,2,3-triazole-4-yl)propane-1,3-diol derivative of novel compound for directly inhibiting ASM activity, and use thereof CHRNB2, ACHE, SMPD2 TDP1 166/4885HCRTR2 500/4885GAA 409/4885
US-20070219163-A1 Compounds Active in Sphingosine 1-Phosphate Signaling S1PR3, S1PR1, S1PR5 TDP1 2226/4885HCRTR2 54/4885GAA 4621/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.